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People with schizophrenia show decreased prefrontal cortex (PFC) activity during emotional
response inhibition, a cognitive process sensitive to hormonal inﬂuences. Raloxifene, a selective
estrogen receptor modulator, binds estrogen receptor alpha (ESR-α), improves memory, attention
and normalizes cortical and hippocampal activity during learning and emotional face recognition in
schizophrenia. Here, we tested the extent to which raloxifene restores neuronal activity during
emotional response inhibition in schizophrenia. Since genetic variation in estrogen receptor alpha
(ESR-1) determines cortical ESR-α production and correlates with cognition, we also predicted that
genetic ESR-1 variation would differentially relate to increased cortical activity by raloxifene
administration. Thirty people with schizophrenia participated in a thirteen-week randomized,
double-blind, placebo-controlled, cross-over adjunctive treatment trial of raloxifene administered
at 120 mg/day. Effects of raloxifene on brain activation were assessed based on ESR-1 genotype
using functional magnetic resonance imaging during emotional word inhibition. Raloxifene
increased PFC activity during inhibition of response to negative words and the raloxifene related
increased PFC activity was greater in patients homozygous for ESR-1 rs9340799 AA relative to G
carriers. Comparison to 23 healthy controls demonstrated that PFC activity of people with
schizophrenia receiving raloxifene was more similar to controls than to their own brain activity
during placebo. Estrogen receptor modulation by raloxifene restores PFC activity during emotional
response inhibition in schizophrenia and ESR-1 genotype predicts degree of increased neuralo.2016.10.009
blished by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
/by-nc-nd/4.0/).
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estrogen receptor genotype. Europeactivity in response to raloxifene. While these preliminary results require replication, they suggest
the potential for personalized pharmacotherapy using ESR-1 and estrogen receptor targeting
compounds in schizophrenia.
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Cognitive deﬁcits, particularly impaired executive control
processes related to response inhibition and working memory,
are core symptoms of schizophrenia (Ravizza et al., 2010;
Weickert et al., 2000), have been linked to impaired prefrontal
cortex (PFC) function (Barch et al., 2001) and worse prognosis
(Green et al., 2000). Decreased PFC activity has been routinely
reported in people with schizophrenia relative to healthy
controls during response inhibition and working memory
(Glahn et al., 2005; Vercammen et al., 2012). Since antipsy-
chotics are unable to restore cognition or dysfunctional cortical
brain activity in people with schizophrenia, there is an urgent
need to identify treatments that can restore the underlying
neural processes and improve attention and memory which are
related to functional capacity.
In light of the need for novel cognitive treatments in
schizophrenia, we have recently reported that the selective
estrogen receptor modulator (SERM), raloxifene, improved
attention and memory in men and women with schizophrenia
(Weickert et al., 2015). While these results are encouraging, the
neural mechanisms underlying raloxifene based improvement are
only beginning to be identiﬁed since different cognitive processes
are often dependent upon speciﬁc brain regions to various
degrees. Thus, we have shown that adjunctive raloxifene
administration can improve brain activity in two distinct brain
regions (hippocampus and inferior frontal gyrus) on the basis of
distinct cognitive tests: one involving implicit learning and one
involving emotional face recognition (Ji et al., 2016; Kindler
et al., 2015). However, we do not know the extent to which
adjunctive raloxifene will restore PFC neural activity during
emotional word inhibition in schizophrenia.
There is abundant evidence for emotional processing
impairments in schizophrenia, with deﬁcits during basic emo-
tion recognition, emotional memory, the experience of affec-
tive states (Schneider et al., 1995), and the recognition and
interpretation of negative emotional content (Kohler et al.,
2003). The emotional go/no-go word inhibition test is con-
sidered to be a complex emotional task that requires the
recognition, processing and inhibition of responses to written
words with negative valence which assesses the emotion-
cognition interaction and robustly activates the PFC
(Vercammen et al., 2012) in healthy participants. Our lab
and others have shown that people with schizophrenia have
impaired accuracy and blunted PFC activity during response
inhibition (Ravizza et al., 2010; Vercammen et al., 2012;
Weisbrod et al., 2000). Furthermore, PFC activity during
response inhibition to emotional words is sensitive to sex
hormones, as activity correlates with circulating estrogen
levels in healthy females (Amin et al., 2006) and with
circulating testosterone in men with schizophrenia
(Vercammen et al., 2013). This suggests that sex hormones,, et al., Raloxifene increases prefr
an Neuropsychopharmacology (20both estrogen and testosterone (which can be converted to
estrogen), may play a role in modulating cortical activity
during evaluating and directing responses to emotive stimuli
and suggests that the emotional go/no go test is an ideal
cognitive task to test the neural response of a novel sex
steroid receptor treatment.
Evidence ranging from clinical behavioral data to mole-
cular neuropathology suggests that estrogen signaling may
be altered in the brains of people with schizophrenia. The
onset of schizophrenia often occurs during late adolescence
(Lieberman et al., 2001), there are sex differences in age of
onset, symptoms of psychosis (Shtasel et al., 1992), and
course of schizophrenia (Gur et al., 1996) and low estrogen/
testosterone levels in females/males with schizophrenia
have been related to worse negative symptoms and more
impaired cognition (Ko et al., 2006; Moore et al., 2013).
Estrogen is a potent regulator of both emotional responses
(Amin et al., 2005) and PFC activity (Berman et al., 1997),
and estrogen therapy improves recovery from acute psy-
chotic symptoms and reduces positive symptoms and gen-
eral anxiety in females with schizophrenia (Kulkarni et al.,
2014). SERMs activate estrogen receptors in brain and bone
but do not stimulate estrogen receptors in breast or uterine
tissue; therefore, reducing the risk of some adverse events
(Lonard and Smith, 2002). Raloxifene, a SERM approved for
use in postmenopausal women for osteoporosis, has been
shown to be effective in enhancing brain activity and
maintaining cognition in older adults (Goekoop et al.,
2006; Yaffe et al., 2005). Raloxifene administration can
also reduce negative symptom severity (Usall et al., 2015),
has beneﬁcial effects on memory and executive function in
postmenopausal women with schizophrenia (Huerta-Ramos
et al., 2014), and improves attention and memory in
younger men and women with schizophrenia (Weickert
et al., 2015) supporting the need for a greater under-
standing of the mechanism by which raloxifene improves
cognition in schizophrenia. Furthermore, we found approxi-
mately 40% of men and women with schizophrenia showed
cognitive improvement with raloxifene administration
(Weickert et al., 2015), suggesting that there is hetero-
geneity in the response to raloxifene treatment. Thus,
identifying biomarkers that predict the neuronal response
to raloxifene would be of clinical value.
The neuronal response to pharmacological treatment in
humans can vary depending on functional genotypes for the
target receptor. The estrogen receptor-α gene (ESR1),
located on chromosome 6q25.1, undergoes complex tran-
scriptional regulation and alternative splicing (Hirata et al.,
2003). While the ESR1 gene contains many variants, two
DNA changes of primary interest are two ESR1 single
nucleotide polymorphisms (SNPs) in intron 1: rs9340799
(A/G) and rs2234693 (T/C) which are in strong linkage
disequilibrium (Becherini et al., 2000) and were related toontal activity during emotional inhibition in schizophrenia based on
16), http://dx.doi.org/10.1016/j.euroneuro.2016.10.009
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2013; Yaffe et al., 2009, 2002). The G and C alleles of
rs9340799 and rs2234693, respectively, are considered risk
alleles for cognitive deﬁcits and schizophrenia (Sundermann
et al., 2010; Weickert et al., 2008). Genetic variation within
intron 1 is associated with reduced ESR-α mRNA levels in the
PFC of men and women with schizophrenia (Perlman et al.,
2005; Weickert et al., 2008). Both ESR1 intron 1 SNPs
(rs9340799 and rs2234693) are functional and regulate the
level of gene transcription (Maruyama et al., 2000).
Our ﬁrst aim was to determine the extent to which
adjunctive raloxifene treatment at 120 mg daily alters neuro-
nal activity during emotional response inhibition in men and
women with schizophrenia. Our hypothesis was that adminis-
tration of the SERM raloxifene would improve emotional
response inhibition and increase PFC neural activity in both
men and women with schizophrenia. Additionally, here, we
report results of the ﬁrst “pharmaconeuroimaging genomics”
study of ESR1 to determine the extent to which the effect of
adjunctive raloxifene therapy on brain activity varies depend-
ing on ESR1 genotype. Speciﬁcally, we predicted the G and C
alleles of ESR1 rs9340799 and rs2234693, respectively would
be associated with less PFC activity and decreased perfor-
mance in people with schizophrenia administered adjunctive
raloxifene during emotional response inhibition.2. Experimental procedures
2.1. Overall organization of this study
There were three separate and main comparisons in the present study.
First, raloxifene and placebo was administered to men and women with
schizophrenia using a randomized, double-blind, placebo-controlled,Figure 1 Flow diagram describ
Please cite this article as: Kindler, J., et al., Raloxifene increases prefro
estrogen receptor genotype. European Neuropsychopharmacology (201cross-over design to determine the extent to which raloxifene inﬂuenced
brain activity during emotional inhibition in schizophrenia. A secondary
analysis in that trial assessing the effects of raloxifene on brain activity
was performed in people with schizophrenia on the basis of their ESR-1
genotype. Finally, in a separate series of analyses, people with schizo-
phrenia receiving raloxifene and the same people with schizophrenia
receiving placebo were compared to a group of healthy adults (not
receiving medication) to determine the extent to which raloxifene
administration to people with schizophrenia can normalize brain activity
in schizophrenia during emotional inhibition.2.2. Participants
Thirty chronically ill adult patients with schizophrenia or schizoaf-
fective disorder (18–55 years of age) were recruited for participa-
tion in the study. These patients were a subset of patients from our
larger trial in which the CONSORT diagram was provided (Weickert
et al., 2015). See Figure 1 for a ﬂow diagram describing this
neuroimaging study. See Table 1a for the demographics and clinical
characteristics of the patients on basis of treatment order. All
patients met the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV) criteria for schizophrenia or schi-
zoaffective disorder on the basis of the Structured Clinical Inter-
view for DSM-IV Axis 1 disorders (SCID) (First, 2007) which was
administered by a trained psychiatrist or psychologist.
All patients were screened for exclusion criteria, which included
a concurrent DSM-IV Axis I diagnosis other than schizophrenia or
schizoaffective disorder, history of uncontrolled diabetes or cardi-
ovascular disease including hypertension, recent alcohol/substance
abuse (within the past 5 years), head injury with loss of conscious-
ness, epileptic seizures, structural brain abnormalities, develop-
mental disorders, mental retardation and/or central nervous
system infection. A four subtest version of the Wechsler Adult
Intelligence Scale, 3rd Edition (WAIS-III) (Wechsler, 1997) and the
Wechsler Test of Adult Reading (WTAR) (Wechsler, 2001) were
administered to all patients to obtain estimates of current IQ anding the neuroimaging study.
ntal activity during emotional inhibition in schizophrenia based on
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Table 1a Demographic summary of patients in raloxifene treatment trial on basis of treatment order.
Schizophrenia total n=21
baseline
placebo treatment
ﬁrst
raloxifene treatment
ﬁrst
df t
value
p
Age 35.5 (7.3) — — — — —
Gender 13 m/ 8f — — — — —
Education 13.6 (2.4) — — — — —
WAIS-III IQ 95.5 (14.2) — — — — —
WTAR 107.5 (8.4) — — — — —
Age of Onset 22.8 (4.1) — — — — —
Duration of
illness
12.8 (7.7) — — — — —
CPZ 479.6 (409.3) 484.0 (424.8) 448.3 (387.0) 20 1.4 0.18
PANSS total 62.6 (19.9) 61.0 (16.7) 59.4 (16.4) 20 1.1 0.37
PANSS pos 15.4 (4.9) 15.2 (5.5) 14.1 (4.8) 20 2.3 0.09
PANSS neg 13.8 (6.6) 13.5 (5.6) 13.0 (5.0) 20 0.9 0.37
Table 1b Demographic comparison of healthy controls and patients with schizophrenia.
Healthy controls n=23 Schizophrenia total n=21 df t value/ Chi-square p
Age 33.4 (7.6) 35.5 (7.3) 42 0.91 0.37
Gender 11m/12f 13m/ 8f 42 0.9 0.35
Education 15.7(1.8) 13.6 (2.4) 42 3.3 0.002*
WAIS-III IQ 114.2(15.4) 95.5 (14.2) 42 4.3 0.001*
WTAR 112.1(4.8) 107.5 (8.4) 42 2.3 0.028*
Notes: means with 7 standard deviations in parentheses. CPZ = mean daily chlorpromazine equivalent dose. PANSS = Positive And
Negative Syndrome Scale. WAIS-III = Wechsler Adult Intelligence Scale, 3rd Edition. WTAR = Wechsler Test of Adult Reading. Healthy
controls were compared to schizophrenia patients at baseline. * p o 0.05 FDR corrected.
J. Kindler et al.4premorbid IQ. All patients were receiving antipsychotic medication
(82% receiving second-generation antipsychotics) for at least 1 year
prior to participation. Mean daily dose of antipsychotic medication
for each person with schizophrenia was converted to approximate
daily mean chlorpromazine milligram equivalents (CPZ) dose using
standard guidelines (Leucht et al., 2003). Symptom severity in
people with schizophrenia was assessed using the Positive and
Negative Syndrome Scale (PANSS) (Kay et al., 1987) by a psychol-
ogist or psychometrician trained in administration and scoring.
Additionally, twenty-three healthy adults were scanned by
functional magnetic resonance imaging (fMRI). See Table 1b for
demographics of the healthy adult group versus patients. Exclusion
criteria for healthy controls included a personal history of or a ﬁrst-
degree relative with a DSM-IV Axis I diagnosis, history of uncon-
trolled diabetes or cardiovascular disease including hypertension,
recent alcohol/substance abuse (within the past 5 years), head
injury with loss of consciousness, epileptic seizures, structural brain
abnormalities, developmental disorders, mental retardation and/or
central nervous system infection.
All participants had normal vision or their vision was corrected to
normal with MRI compatible lenses. All procedures were approved
by the University of New South Wales and the South Eastern Sydney
and Illawarra Area Health Service Human Research Ethic Commit-
tees. The procedure was explained and written informed consent
was obtained from each participant before entry into the study.2.3. Raloxifene treatment
During the ﬁrst six-week phase of a thirteen week, randomized,
placebo-controlled, double blind, cross- over trial schizophrenia
patients received 120 mg encapsulated raloxifene (2 60 mg, oralPlease cite this article as: Kindler, J., et al., Raloxifene increases prefr
estrogen receptor genotype. European Neuropsychopharmacology (20administration) daily in the active condition or oral administration
of two placebo (lactose) capsules daily in the placebo condition as
an adjunctive treatment to their current antipsychotic medication.
Following treatment in the ﬁrst 6-week phase, patients entered a
one-week wash-out, raloxifene half-life=27.7 h, (Lilly, 2007) fol-
lowed by the second 6-week phase consisting of the alternate
treatment (raloxifene or placebo). Several studies have shown
beneﬁcial effects of raloxifene treatment at a daily dosage of
120 mg orally to reduce symptom severity in postmenopausal
females with schizophrenia (Kulkarni et al., 2010) or to improve
or preserve cognition and maintain brain activity in healthy aging
(Goekoop et al., 2006).
Patients were monitored on a weekly basis to assess potential
adverse events and self-reported compliance (compliance was also
determined by returned pill counts). Additional methods for
monitoring treatment compliance were achieved through the
collection of blood samples for circulating hormones and clotting
factors affected by treatment at baseline, 6 and 13 week assess-
ments. The trial was registered prior to initiation with the
Australian and New Zealand Clinical Trials Registry (ANZCTR num-
ber: 12608000461392).2.4. fMRI methods
2.4.1. Scanning procedure
A 3 T Phillips Achieva MRI scanner with an 8 channel birdcage head
coil at Neuroscience Research Australia, Randwick, Australia was
used to collect imaging data. In total, 162 whole-brain EPI images,
TR/TE=3000/30; 45 interleaved slices, thickness=3 mm, gap=0.3
mm; voxel size 2.14 2.14 3 mm; ﬂip angle=901; FOV=240 mm
were acquired. A T1-weighted high-resolution anatomical scan wasontal activity during emotional inhibition in schizophrenia based on
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5Raloxifene increases prefrontal activity in schizophrenia based on ESR1 genotypeobtained for each participant for registration purposes, TR/TE =
5.3/2.4; 180 slices, thickness = 1 mm, no gap; voxel size 1 1 1
mm; FOV = 256 mm.
2.4.2. Emotional Go/No-Go task
All participants received detailed verbal instructions before the
fMRI scan and the experimenter veriﬁed that the participant had an
adequate comprehension of the procedure. Details of the emotional
go/no-go task have been reported elsewhere (Amin et al., 2006;
Vercammen et al., 2012, 2013). The task included 4 conditions: 1)
attend negative: responding to negative words while inhibiting
responses to neutral words, 2) inhibit negative: responding to
neutral words while inhibiting responses to negative words, 3)
attend positive: responding to positive words while inhibiting
responses to neutral words, and 4) inhibit positive: responding to
neutral words while inhibiting responses to positive words. The
words were selected from the “Affective Norms for English Words”
stimulus set (Bradley and Lang, 1999).
“Negative target/neutral distracter” and “neutral target/negative
distracter” conditions were identical with respect to stimuli; and
likewise for the “positive target/neutral distracter” and “neutral
target/positive distracter” conditions. At the start of each condition,
the words “neutral,” “positive” or “negative” appeared in capital
letters to indicate to which valence the participant was to attend and
respond to. For the fMRI scan, participants were instructed to respond
as quickly as possible to stimuli of the speciﬁed valence (targets), but
to ignore stimuli of other valences (distracters). Each trial consisted of
a ﬁxation cross for 300 ms, a word stimulus presented in the centre of
the screen for 300 ms and a 900 ms response interval. The 4 conditions
were presented in pseudo-randomized order in a block design. Each
block consisted of 10 stimulus presentations and each condition was
presented 4 times for a total of 160 stimulus presentations. There
were 30 seconds of ﬁxation to a crosshair at the initiation and
conclusion of the task. Stimuli were presented on an inverted
computer screen that participants viewed in a mirror mounted in
the head coil and responses were recorded using a ﬁbre optic response
pad (Lumina Systems) that recorded accuracy (percent correct) and
reaction time (ms) data.
2.4.3. fMRI processing
All processing and analyses were performed with SPM8 (Wellcome
Trust Centre for Neuroimaging) and MATLAB. We focused on words
with negative valence, as negative emotion has been shown to have
stronger interference effects on cognitive processing in schizophre-
nia, with robust activation differences between healthy controls
and patients in the PFC (Vercammen et al., 2012) and sex steroid
hormones have been shown to modulate PFC activity during
inhibition of negative words (Vercammen et al., 2013).
All data sets were screened for excessive motion (43 mm in x, y
or z directions or 431 rotation) and magnetic resonance imaging
artifacts. Movement parameters were included as regressors in the
ﬁrst-level model. Three dummy scans were obtained before each
fMRI data acquisition to allow for the equilibration of the MRI signal.
Functional images were realigned to the ﬁrst image in the time
series and co-registered to the anatomical image. All images were
normalized to the Montreal Neurological Institute (MNI) anatomical
template using a nonlinear 12-parameter afﬁne transformation.
Images were smoothed with a 10-mm full width half maximum
Gaussian kernel.
2.5. Genotyping and fMRI analyses based on ESR1
genotype
Genotyping was performed using Applied Biosystems (Mulgrave, VIC,
Australia) TaqMan SNP assays designed for use with an ABI Prism
7900HT Fast Real Time quantitative PCR system for the ESR-1 SNPs
rs2234693 (T/C) and rs9340799 (A/G). All SNPs were in Hardy–Please cite this article as: Kindler, J., et al., Raloxifene increases prefro
estrogen receptor genotype. European Neuropsychopharmacology (201Weinberg equilibrium. The genotype distribution in patients (n=21)
for rs9340799 was AA n=9, AG n=9, GG n=3, and for rs2234693: CC
n=6, TC n=11, TT n=4. Thus, for rs9440799, homozygous G and
heterozygous AG were combined to form a G carrier group, and for
rs2234693, homozygous T and heterozygous TC were combined to
form a T carrier group.
DNA was isolated from 8 ml samples of whole blood collected in
EDTA tubes using a PUREGENE DNA puriﬁcation kit (QIAGEN,
Chadstone Centre, VIC, Australia) following the manufacturer's
protocols. Genomic DNA from each individual was prepared at a
dilution of 10 ng/μl. A PCR solution consisting of 2.5 μl of 2
Universal mastermix with ROX, 0.125 μl genotyping probe and
0.375 μl double-distilled H2O was prepared, added into a 384-well
plate containing 1 μl of genomic DNA from each sample and
pipetted up and down to ensure the genomic DNA and PCR solution
were sufﬁciently mixed. After PCR ampliﬁcation, all SNP genotyping
results were analysed with Sequence Detection Software version 2.3
(ABI, Life Technologies, Mulgrave, VIC, Australia).
2.6. Statistics
2.6.1. Demographic, symptom and behavioral analyses
Fisher's exact tests were calculated for nominal data, paired t-tests
for continuous and normally distributed data comparing raloxifene
and placebo, and independent two sample t-tests for continuous
and normally distributed data comparing healthy controls sepa-
rately to raloxifene or placebo conditions. Paired t-tests were
performed on the mean percentage correct, mean percentage of
false alarms and omissions, and on mean reaction times (RTs) for
‘GO’ trials between placebo and raloxifene conditions. Independent
two sample t-tests were performed on the mean percentage
correct, mean percentage of false alarms and omissions, and on
mean RTs during ‘GO’ trials comparing healthy controls separately
to patients receiving placebo or raloxifene. Symptom severity as
measured by PANSS total, positive and negative symptom severity
scores during raloxifene and placebo conditions were compared
with paired t-tests. Results were false discovery rate (FDR) cor-
rected for multiple testing. Signiﬁcance level was set at po0.05,
two-tailed. Statistics were performed in SPSS 20.0.
2.6.2. fMRI analyses
Emotional Go/No-Go task, scanning procedure and fMRI preproces-
sing were identical for healthy controls and patients with schizo-
phrenia. In the patients, scans during active and placebo conditions
were obtained at the conclusion of weeks 6 and 13. We excluded
one patient because of incidental ﬁndings of abnormalities on
structural MRI, three patients because of excessive movement,
and ﬁve patients due to insufﬁcient behavioral data, yielding 21
patients in the within-subjects design analysis. To avoid circularity
between our main analysis (raloxifene treatment in schizophrenia)
and our functional ROI analysis, the functional ROIs were derived
from an independent sample of twenty-three healthy controls using
a one-sample t-test of activated regions during the inhibition of
negative versus neutral words in healthy adults to design the
bilateral PFC mask region of interest (ROI) consisting of BA10 and
BA9, see Figure 2 and Vercammen et al. ( 2012). At the ﬁrst level of
analysis, the contrast of interest was deﬁned as condition 2 (inhibit
responses to negative words) minus condition 1 (inhibit responses to
neutral words) to assess the magnitude of the difference in blood
oxygenation level-dependent (BOLD) signal for inhibiting responses
to negative words. Signiﬁcance level was set at po0.05, FDR
corrected.
At the second level analysis, a paired t test was performed
comparing the raloxifene condition to the placebo condition with
performance as a covariate. Signiﬁcant differences were threshold
free cluster enhancement (TFCE) family wise error (FWE) and small
volume corrected (po0.05) with a mask for the region of interestntal activity during emotional inhibition in schizophrenia based on
6), http://dx.doi.org/10.1016/j.euroneuro.2016.10.009
Figure 2 PFC mask BA 9 and 10 based on regions activated during inhibition of negative versus neutral words in healthy adults.
DLPFC mask in white. The mask was designed from the one sample t-test of healthy participants, FDR corrected, po0.05, conﬁned
to prefrontal cortex (Vercammen et al., 2012).
Figure 3 Effects of raloxifene relative to placebo on BOLD activity during inhibition of negative words in people with
schizophrenia. Raloxifene 4 placebo, po0.005, cluster size 4 50 (whole brain, uncorrected, for visualization). x/y/z= 30/
44/20, T=4.17, Z=3.47, BA10, 59 voxels, left dorsolateral prefrontal cortex. Yellow areas show signiﬁcantly increased BOLD signal
in the raloxifene treatment group as compared to placebo.
J. Kindler et al.6(PFC). To evaluate sex differences on fMRI BOLD signal, a sex-by-
drug treatment interaction was assessed in SPM, using a ﬂexible
factorial design. Sex differences with respect to the response to
raloxifene (raloxifene – placebo treatment) were also evaluated for
behavioral measures (mean percent correct and mean
reaction time).
2.6.3. fMRI, genotype and raloxifene treatment analyses
Genotype effects were modeled and tested within SPM performing a
two-sample t-test (raloxifene-placebo difference). Allelic combina-
tions were grouped in order to increase the sample size of the minor
allele frequency groups for comparison, rs9340799: AA (n=9) versus
G carriers (n=12), rs2234693: CC (n=6) versus T carriers (n=15).
The results of an independent whole-brain analysis, representing
the largest sample of healthy adults (N=43) performing the
emotional go/no-go task in fMRI to date, contrasting the conditions
“inhibit negative-attend neutral” (Vercammen et al., 2014) showed
increased activation in healthy controls during the inhibition of
responses to negative words relative to neutral words in a pre-
dominantly prefrontal network of brain regions with a peak at x/y/
z = 28/52/10 (right middle frontal gyrus, BA 10). Thus, a small
volume correction of our genotype results was performed at x/y/z
= 28/52/10 with a sphere of 10 mm. Additionally, effects of
rs2234693 and rs9340799 genotypes on behavioural measures (mean
percent correct and mean reaction time) were also evaluated
(raloxifene – placebo treatment, difference score).
2.6.4. fMRI healthy control versus schizophrenia raloxifene
and placebo condition analyses
Given the increased activity in the PFC with raloxifene treatment
(see Results), BOLD signal beta weights were also extracted from
healthy participants (n=23) for separate comparisons of healthy
controls with patients receiving raloxifene and the same patients
during placebo treatment. Paired t-tests of raloxifene versusPlease cite this article as: Kindler, J., et al., Raloxifene increases prefr
estrogen receptor genotype. European Neuropsychopharmacology (20placebo and independent two sample t-tests of healthy controls
versus patients receiving raloxifene and healthy controls versus
patients receiving placebo were performed. All results were FDR
corrected for multiple testing.3. Results
3.1. Demographics
For demographics and symptom severity of the patients in
the raloxifene treatment trial see Table 1a. All patients
were chronically ill and displayed mild to moderate symp-
tom severity based on their PANSS scores. Demographic
comparison of the patients with schizophrenia and healthy
adults are provided in Table 1b.3.2. Effects of raloxifene
3.2.1. Raloxifene increases PFC BOLD activity during
emotional inhibition
Relative to placebo, raloxifene treatment was associated
with increased fMRI BOLD activity in the left PFC (BA10, x/
y/z=30/44/20, T=4.17, Z=3.47, df=20, TFCE FWE small
volume corrected, po0.05, see Figure 3) during inhibition
of responses to negative words in people with schizophre-
nia. Within the region of interest, patients receiving
placebo did not display signiﬁcantly greater BOLD activity
than the same patients receiving raloxifene. No signiﬁcant
differences were detected between male and female
patients for raloxifene versus placebo conditions in relationontal activity during emotional inhibition in schizophrenia based on
16), http://dx.doi.org/10.1016/j.euroneuro.2016.10.009
Table 2 Group means and standard deviations for
behavioural performance parameters on the emotional
Go/No-Go task in patients with schizophrenia during
raloxifene and placebo treatment.
Placebo
treatment
Raloxifene
treatment
t-value p-value
Inhibit
negative–
respond
neutral
Inhibit
negative–
respond
neutral
RT 1075 (280) 1098 (310) 0.70 0.49
Accuracy 73 (9) 67 (10) 1.80 0.34
False alarms 0.7 (0.7) 1.0 (0.9) 1.44 0.34
Omissions 2.0 (0.9) 2.2 (1.0) 0.77 0.49
Reaction time (RT), mean (sd) in milliseconds; Accuracy:
mean (sd) in percent correct; False alarm errors: mean
number (sd); Omissions: mean number (sd); df=20.
Table 3 Group means and standard deviations for
behavioral performance parameters on the emotional
Go/No-Go task at week 6 versus week 13 regardless of
treatment condition, testing for order effects.
Time 1 Time 2 t-value p-value
Inhibit
negative–
respond
neutral
Inhibit
negative–
respond
neutral
RT 1087 (303) 1086 (288) 0.02 0.98
Accuracy 66 (7) 74 (11) 3.3 0.006
False
alarm
errors
0.8 (0.9) 0.9 (0.8) 0.42 0.91
Omissions 2.6 (0.9) 1.7 (0.7) 5.3 0.004
Notes: Reaction time (RT), mean (sd) in milliseconds;
Accuracy: mean (sd) in percent correct; False alarm errors:
mean number (sd); Omissions: mean number (sd) paired
t-test, df=20.
7Raloxifene increases prefrontal activity in schizophrenia based on ESR1 genotypeto BOLD signal in the ROI (no signiﬁcant voxels at po0.001
in F or t contrasts within the ROI).3.2.2. Symptom severity and behavior analyses
Similar to our ﬁnding in our larger sample, raloxifene
treatment had no signiﬁcant effects on PANSS total, PANSS
negative or PANSS positive symptom severity scores in this
subset of participants (Table 1a). In relation to the emo-
tional go/no-go task, raloxifene treatment had no signiﬁ-
cant effect on reaction time, no signiﬁcant effect on
accuracy, omissions or false alarms during inhibition of
negative words (see Table 2 for means and standard
deviations in relation to performance). A separate analysis
of behavior performance at week 6 versus week 13 regard-
less of treatment condition (raloxifene or placebo) was
performed to test for order effects (see Table 3). APlease cite this article as: Kindler, J., et al., Raloxifene increases prefro
estrogen receptor genotype. European Neuropsychopharmacology (201signiﬁcant improvement between week 6 and week 13,
regardless of treatment condition, was obtained in relation
to performance (see Table 3). Patients receiving raloxifene
and patients receiving placebo were also compared to
healthy controls in relation to percent correct, false alarms,
omissions, and RT during “Go trials.” There were signiﬁcant
differences between healthy controls and patients receiving
raloxifene and between healthy controls and patients
receiving placebo in relation to the performance variables
(see Table 4). No signiﬁcant differences were found
between male and female participants in raloxifene versus
placebo conditions in relation to performance accuracy
(raloxifene – placebo difference score, males versus
females, t=0.313, df=19, p=0.76) or reaction time (ralox-
ifene-placebo difference score, males versus females,
t=1.18, df=19, p=0.25).
3.2.3. ESR-1 genotype predicts increased PFC BOLD
activity to raloxifene treatment
In the raloxifene relative to placebo comparison, patients
with schizophrenia who had ESR-1 genotype rs9340799 A/A
(n=9) showed signiﬁcantly increased fMRI BOLD activity in
bilateral PFC (middle frontal gyrus, BA 10) relative to G
allele carriers (n=12) during inhibition of responses to
negative words (see Figure 4). The signal in the right middle
frontal gyrus (x/y/z = 32/58/14) remained signiﬁcant after
small volume and FWE correction (p o 0.041). Concurrent
with the increased PFC activity in response to raloxifene,
we also showed that those patients who were ESR-1
genotype rs9340799 A/A homozygotes showed signiﬁcantly
greater accuracy relative to G-carriers (z=2.6, p=0.04).
There was no signiﬁcant genotype difference in relation to
reaction time (z=0.07, p=0.97).
In contrast, patients with schizophrenia who varied on
ESR-1 genotype rs2234693 did not show a signiﬁcant differ-
ence in raloxifene related BOLD response, reaction time
(z=1.4, p=0.32), or accuracy (z=0.01, p=0.97).
3.3. Comparison of healthy controls and patients
during raloxifene and placebo treatment
To determine the extent to which the raloxifene-related
BOLD activity approached normal levels, fMRI BOLD signal
beta estimates in the left PFC (BA10, x/y/z=30/44/20),
were compared separately in healthy controls and patients
with schizophrenia during raloxifene and placebo treat-
ments (see Figure 5). When comparing healthy controls to
patients receiving raloxifene, no signiﬁcant differences
were found (t=0.36, df=42, p=0.72); however, signiﬁ-
cantly less fMRI BOLD activity (deactivation) was found in
these same patients receiving placebo relative to raloxifene
treatment (t=3.82, df=20, p=0.003) and in the same
patients receiving placebo compared to healthy controls
(t=3.14, df=42, p=0.005).
4. Discussion
The results of this study demonstrate that estrogen receptor
modulation with raloxifene increases PFC activity in schizo-
phrenia during an emotional response inhibition task.
Importantly, both performance accuracy and the fMRI BOLDntal activity during emotional inhibition in schizophrenia based on
6), http://dx.doi.org/10.1016/j.euroneuro.2016.10.009
Table 4 Group means and standard deviations for behavioral performance parameters of healthy controls and schizophrenia
patients receiving raloxifene or placebo on the emotional Go/No-Go task.
Healthy Controls Schizophrenia placebo t-value p-value Schizophrenia raloxifene t-value p-value
RT 942(163) 1075(280) 1.9 0.058 1098 (310) 2.1 0.055
Accuracy 82(11) 73(9) 3.2 0.006 67 (10) 4.7 0.002
False alarms 3.7(3.0) 0.7(0.7) 4.5 0.001 1.0 (0.9) 3.9 0.002
Omissions 3.4(2.9) 2.0(0.9) 2.1 0.044 2.2 (1.0) 1.8 0.086
Notes: Reaction time (RT), mean (sd) in milliseconds; Accuracy: mean (sd) in %; False alarm errors: mean number (sd); Omissions:
mean number (sd), 2 sample t-test, df= 42.
Figure 4 Raloxifene effects (raloxifene-placebo difference) on the basis of ESR-1 rs9340799 genotypes, 2 sample t-test, AA (n=9)
versus G carriers (n=12). Yellow areas show signiﬁcantly higher BOLD signal in AA homozygotes relative to G carriers (BA 9 & 10,
bilaterally, p o 0.005, uncorrected).
Figure 5 fMRI BOLD signal beta estimates (mean+/-sd) in dorsolateral prefrontal cortex, BA10, x/y/z=30/44/20, showing
raloxifene, n=21 (beta values 0.13470.262), placebo, n=21 (beta values 0.05470.278) and healthy controls, n=23 (beta values
0.15770.158) comparisons. During raloxifene treatment patients activated the PFC (not signiﬁcantly different than healthy
controls) whereas during placebo treatment patients showed PFC deactivation. **p=0.005, ***p=0.003.
J. Kindler et al.8signal increased during inhibition of response to negative
words while receiving raloxifene for the ESR-1 rs9340799
A/A genotype, demonstrating a pharmacogenetic interac-
tion. However, we did not ﬁnd a behavioral difference in
response accuracy to negative words in the overall sample
of people with schizophrenia during raloxifene administra-
tion, suggesting that assessing neuronal responses at thePlease cite this article as: Kindler, J., et al., Raloxifene increases prefr
estrogen receptor genotype. European Neuropsychopharmacology (20level of cortical physiology may either be a more sensitive
indicator of treatment response (Bookheimer et al., 2000)
or the physiological effect may be large enough to detect
prior to any noticeable change in behavior and without
taking genotype effects into account.
We have previously demonstrated that patients with schizo-
phrenia show signiﬁcantly attenuated BOLD response in the PFContal activity during emotional inhibition in schizophrenia based on
16), http://dx.doi.org/10.1016/j.euroneuro.2016.10.009
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controls (Vercammen et al., 2012). The increase of BOLD signal
with raloxifene treatment in the present study suggests restora-
tion of PFC neuronal activity. The comparative analysis between
patients and healthy controls performed here, demonstrates
decreased BOLD signal in the PFC in patients receiving placebo
relative to healthy controls, but an increase of PFC BOLD activity
during raloxifene treatment relative to placebo, which we
interpret here to be potentially restorative.
This supports our previous work showing that raloxifene
administration increases activity in brain regions relevant to
speciﬁc cognitive domains in schizophrenia, such as the
inferior frontal gyrus during emotional face recognition (Ji
et al., 2016). During implicit probabilistic association learn-
ing, raloxifene also increases activity in brain regions (e.g.,
hippocampus) of people with schizophrenia that are not
typically elicited in healthy participants. However, people
with schizophrenia who learn the associations without
raloxifene treatment show increased activity in medial
temporal lobe structures (Weickert et al., 2009) and this
region overlaps with the region of activity during probabil-
istic association learning with raloxifene administration in
schizophrenia (Kindler et al., 2015). Taken together, our
results suggest that while widespread areas of the tele-
ncephalon can become more activated with raloxifene
treatment, not all brain areas appear equally responsive
to raloxifene in people with schizophrenia.
Our larger raloxifene trial demonstrated beneﬁcial effects
of raloxifene on attention in schizophrenia (Weickert et al.,
2015). Both, attention and response inhibition are dependent
on healthy PFC function (Asplund et al., 2010; Vercammen
et al., 2012). As our trial used a within-subjects design, the
brain response to raloxifene cannot be explained by differ-
ences in age, sex, baseline cognitive performance, or
chlorpromazine equivalent dose, which did not differ sig-
niﬁcantly between treatment arms. There is a very limited
number of reports on treatments that improve PFC activity/
function in schizophrenia, such as transcranial direct current
stimulation (Vercammen et al., 2011) or adjunctive medica-
tion (Minzenberg et al., 2015), whereas antipsychotics
appear to have negative effects on PFC (Keedy et al., 2015).
Our results provide the ﬁrst support for the use of ESR1
genotype to predict neural response to raloxifene. We ﬁnd
increased PFC activity with raloxifene treatment in people with
schizophrenia who carry A/A (non-risk) genotype at rs9340799.
This suggests that the rs9340799 AA genotype group may be
more amenable to treatment via the ESR1 signaling pathway.
The majority of case-control studies indicated an increased risk
of cognitive impairment for both the G and C alleles of rs9340799
and rs2234693 respectively (Sundermann et al., 2010). At a
molecular level, reductions in ESR-α mRNA in the frontal cortex
of patients with schizophrenia have been reported in rs2234693
C carriers (Perlman et al., 2005; Weickert et al., 2008); however,
both SNPs appear to control ESR-α transcription in vitro
(Maruyama et al., 2000) and our results suggest that rs9340799
may have more penetrative effects in a raloxifene treatment
context in humans. While these preliminary genotype based
treatment response results may help to formulate beneﬁcial
treatment predictions to raloxifene based on ESR1 genotypes,
further work conﬁrming the utility of this particular functional
ESR1 SNP in larger clinical trials and encompassing more diverse
treatment outcomes would be needed to begin to tailorPlease cite this article as: Kindler, J., et al., Raloxifene increases prefro
estrogen receptor genotype. European Neuropsychopharmacology (201treatments to those likely to derive the most beneﬁcial response
based on this potential biomarker.
In addition to the limited sample size for a genetic analysis of
this ﬁrst pharmacoimagingenomics report of an ESR1 genetic
impact on the brain response to raloxﬁene treatment, there are
some additional limitations to the present study. One concern
with using a cross-over clinical trial design pertains to potential
carryover effects. Although raloxifene has a half-life of only 27
hours, it may have long-term effects such as changing gene
expression, thereby promoting neuronal protection, synaptic
growth and a reduction of neuroinﬂammation (Wang et al.,
2004). A learning effect or carryover effect (Yaffe et al., 2005)
might explain the behavioral improvement that is sustained in
the total group between week 6 and week 13, regardless of
treatment condition. Future studies may want to use a parallel
group design to assess potential long lasting effects of raloxifene.
However, the groups were balanced for order of administration
(i.e., active or placebo ﬁrst) and any potential carryover effects
would have reduced the effect of interest, i.e., comparing
raloxifene to placebo. Thus, it seems unlikely that a putative
carryover effect of raloxifene on BOLD response would be
responsible for our ﬁndings of signiﬁcantly increased PFC activity
with raloxifene treatment. We did not detect differences in
performance between raloxifene and placebo treatment in the
overall sample. However, importantly, the effects of estrogen
therapy may be more manifest at the physiological level as is
supported by the concordance between BOLD activity and
performance in the subgroup of patients with a greater response
to raloxifene (ESR1 rs9340799 AA genotype). Pharmacoimaging
directly assesses neurophysiological changes and may have a
greater sensitivity to detect effects of raloxifene on brain
activity, relative to behavioral tests alone. Previous studies have
shown that BOLD activity can be more sensitive to neural change
than behavioral measures alone and can predict cognitive
decline (Bookheimer et al., 2000).
Overall, the results of the present study demonstrate
that six weeks of the SERM raloxifene treatment increases
PFC activity during emotional response inhibition in people
with schizophrenia. The study provides direct evidence for
the impact of the SERM raloxifene on brain activity in
regions known to be important in the pathophysiology of
cognitive deﬁcits in schizophrenia. The strength of the
response was modulated by speciﬁc genotypes as patients
homozygous for the A allele of the ESR-1 rs9340799 geno-
type showed increased PFC activity with raloxifene com-
pared to G carriers. Together, these results suggest the
potential for a personalized pharmacotherapy aimed at
using estrogen receptor targeting compounds to restore
brain activity and cognition in schizophrenia.
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